Biodexa Pharmaceuticals (BDRX)
3.29
-0.16 (-4.64%)
At close: Feb 28, 2025, 3:58 PM
3.24
-1.67%
After-hours: Feb 28, 2025, 04:56 PM EST
Biodexa Pharmaceuticals Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Cash & Equivalents | 5.97M | 2.84M | 10.06M | 7.55M | 10.93M | 2.34M | 13.2M | 17.61M | 16.18M | 30.32M | 2.39M | 133K |
| Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12K | 49K |
| Other Long-Term Assets | n/a | -837K | -1.15M | -542K | 2.63M | 469K | 465K | 448K | 387K | 425K | 379K | -927K |
| Receivables | 704K | 329K | 33K | 95K | 22K | 89K | 2.23M | 1.43M | 985K | 189K | 160K | n/a |
| Inventory | -704K | 1.00 | 1.00 | -1.38M | 1.00 | n/a | 941K | 817K | 459K | n/a | n/a | n/a |
| Other Current Assets | 1.06M | 376K | 607K | 258K | 2.79M | 3.19M | 2.21M | 2.45M | 2.71M | 1.11M | 1.55M | 964K |
| Total Current Assets | 7.03M | 4.69M | 11.76M | 9.28M | 13.74M | 5.62M | 18.58M | 22.3M | 20.33M | 31.63M | 4.09M | 1.1M |
| Property-Plant & Equipment | 571K | 831K | 1.15M | 542K | 2.15M | 1.98M | 2.53M | 2.77M | 1.98M | 1.52M | 684K | 876K |
| Goodwill & Intangibles | 2.94M | 6K | n/a | n/a | 12.38M | 12.37M | 27.65M | 31.17M | 41.34M | 13.09M | 4K | 2K |
| Total Long-Term Assets | 3.51M | 837K | 1.15M | 542K | 17.16M | 14.83M | 30.64M | 34.39M | 43.71M | 15.04M | 1.08M | 927K |
| Total Assets | 10.54M | 5.53M | 12.91M | 9.82M | 30.89M | 20.44M | 49.22M | 56.69M | 64.04M | 46.66M | 5.17M | 2.22M |
| Account Payables | 314K | 339K | 485K | 337K | 725K | 286K | 2.27M | 3.27M | 2.29M | 981K | 522K | 563K |
| Deferred Revenue | n/a | 197K | n/a | 68K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Short-Term Debt | 169K | 161K | 146K | 200K | 412K | 368K | 361K | 538K | 442K | 491K | 1.25M | n/a |
| Other Current Liabilities | 5.02M | 1.32M | 1.15M | 2.42M | 4.44M | 1.82M | 5.73M | 5.54M | 6.37M | 1.36M | 568K | 4.5M |
| Total Current Liabilities | 5.57M | 1.9M | 1.84M | 2.99M | 5.67M | 2.47M | 8.36M | 9.35M | 9.1M | 2.83M | 2.29M | 5.07M |
| Long-Term Debt | 295K | 463K | 620K | 60K | 5.67M | 884K | 6.18M | 1.62M | 1.51M | 1.49M | 2.12M | 2.17M |
| Other Long-Term Liabilities | n/a | n/a | -469 | 50K | n/a | 165K | n/a | n/a | 6.55M | 354K | n/a | -2.17M |
| Total Long-Term Liabilities | 295K | 463K | 619.53K | 110K | 5.67M | 1.05M | 6.18M | 1.62M | 8.05M | 1.84M | 2.12M | 2.17M |
| Total Liabilities | 5.86M | 2.36M | 2.46M | 3.1M | 11.34M | 3.52M | 14.55M | 10.96M | 17.15M | 4.67M | 4.41M | 7.31M |
| Total Debt | 464K | 624K | 766K | 260K | 6.08M | 1.17M | 6.51M | 2.13M | 1.88M | 1.94M | 3.32M | n/a |
| Common Stock | 1.19M | 1.11M | 98.47K | 63K | 23K | 3K | 3K | 2K | 2K | 1K | n/a | n/a |
| Retained Earnings | -144.77M | -135.34M | -127.8M | -122.43M | -99.84M | -89.72M | -74.65M | -59.11M | -39.15M | -29.22M | -20.4M | -17.19M |
| Comprehensive Income | 61.52M | 53M | 53M | 53M | 53.49M | 53.7M | 56.39M | 57.62M | 54.39M | 39.57M | 142K | n/a |
| Shareholders Equity | 4.68M | 3.16M | 10.45M | 6.72M | 19.56M | 16.92M | 34.68M | 45.72M | 46.89M | 41.99M | 760K | -5.09M |
| Total Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12K | 49K |